120 related articles for article (PubMed ID: 29776903)
1. Prolonged survival with maintenance pemetrexed for a multiple primary malignancy.
Shuayb M; Reza MS
BMJ Support Palliat Care; 2019 Mar; 9(1):51-53. PubMed ID: 29776903
[TBL] [Abstract][Full Text] [Related]
2. Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system.
Pérez-Moreno MA; Cotrina-Luque J; Galván-Banqueri M; Flores-Moreno S; Bautista-Paloma FJ; Calleja-Hernández MÁ
J Chemother; 2015; 27(6):371-7. PubMed ID: 25971603
[TBL] [Abstract][Full Text] [Related]
3. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
Sakhri L; Pinsolle J; Moro-Sibilot D; Pluchart H
J Med Case Rep; 2017 Sep; 11(1):262. PubMed ID: 28915906
[TBL] [Abstract][Full Text] [Related]
4. [A case of Carboplatin and pemetrexed combination chemotherapy for synchronous double cancers of hepatocellular carcinoma and primary lung cancer].
Okamoto E; Sato J; Sema M; Hayasaka J; Watanabe A; Takagi K; Kusano-Kitazume A; Tamura A; Kondo M; Sakuranaka H; Ochi J; Hanada S; Tanaka M; Akita H; Tei S; Ichioka M; Shibayama T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2154-6. PubMed ID: 25731454
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
6. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
7. Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy.
Kaneki T; Koizumi T; Kawashima A; Tsushima K; Kubo K; Fujimoto K; Honda T; Akamatsu T
J Gastroenterol; 2000; 35(11):864-9. PubMed ID: 11085497
[TBL] [Abstract][Full Text] [Related]
8. Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone.
Li C; Wang J; Shao JB; Zhu LM; Sun ZG; Zhang N
Thorac Cancer; 2019 Jul; 10(7):1628-1635. PubMed ID: 31243894
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
Ou W; Li N; Wang SY; Li J; Liu QW; Huang QA; Wang BX
Cancer; 2016 Mar; 122(5):740-7. PubMed ID: 26700505
[TBL] [Abstract][Full Text] [Related]
10. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
[TBL] [Abstract][Full Text] [Related]
11. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
12. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Gridelli C; de Marinis F; Pujol JL; Reck M; Ramlau R; Parente B; Pieters T; Middleton G; Corral J; Winfree K; Melemed S; Zimmermann A; John W; Beyrer J; Chouaki N; Visseren-Grul C; Paz-Ares LG
J Thorac Oncol; 2012 Nov; 7(11):1713-21. PubMed ID: 23059776
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland-type lung adenocarcinoma diagnosed due to esophageal stricture: A case report.
Kawakado K; Tamura T; Nakanishi M; Makimoto G; Sato Y; Kuyama S
Thorac Cancer; 2021 Sep; 12(18):2513-2516. PubMed ID: 34369074
[TBL] [Abstract][Full Text] [Related]
16. Synchronous double primary lung cancers with different response to pemetrexed.
Umemura S; Yamane H; Yano T; Hoshika T; Shiote Y; Takigawa N; Suwaki T; Shirakawa A; Kamei H
Anticancer Drugs; 2011 Jun; 22(5):473-6. PubMed ID: 21346552
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience.
Paliwal P; Rajappa S; Santa A; Mohan M; Murthy S; Lavanya N
Indian J Cancer; 2017; 54(1):197-202. PubMed ID: 29199690
[TBL] [Abstract][Full Text] [Related]
19. Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study.
Zhu W; Røe OD; Wu C; Li W; Guo R; Gu Y; Liu Y; Shu Y; Chen X
J Chemother; 2015 Aug; 27(4):221-6. PubMed ID: 25735792
[TBL] [Abstract][Full Text] [Related]
20. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
Novello S; Scagliotti G; de Castro G; Kiyik M; Kowalyszyn R; Deppermann KM; Arriola E; Bosquee L; Novosiadly RD; Nguyen TS; Forest A; Tang S; Kambhampati SRP; Cosaert J; Reck M
J Thorac Oncol; 2017 Feb; 12(2):383-389. PubMed ID: 27464970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]